Rapport Therapeutics, Inc. Common Stock

RAPPNASDAQ • USD
25.75 USD
↘ 0.40 (1.53%)🟢PRE MARKET (AS OF 06:07 AM EST)
🟢Market: OPEN

RAPP is currently priced at $25.75. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, RAPP trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 13, 2026.

Open?$25.75
High?$25.75
Low?$25.75
Prev. Close?$26.15
Volume?4
Avg. Volume?1.2M
VWAP?$25.75
Rel. Volume?0.00x
Bid / Ask
Bid?$21.93 × 100
Ask?$29.69 × 100
Spread?$7.76
Midpoint?$25.81
Valuation & Ratios
Market Cap?1.6B
Shares Out?59.3M
Float?28.1M
Float %?58.5%
P/E Ratio?N/A
P/B Ratio?3.96
EPS?-$2.54
Dividend?0.00%
Ex-Dividend?N/A
RelatedSNTG
News
Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Employees
84
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-06-07
Address
99 HIGH STREET
BOSTON, MA 02110
Phone: 857-321-8020
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
36
Piotroski F-Score?0/9Weak
Altman Z-Score?32.64Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?14.10%High
Short Interest?4.0M
Days to Cover?1.8
Free Float28.1M
Avg Daily Volume2.2M
Settlement Date2026-10-30
Financial Health
Current Ratio?20.07Strong
Quick Ratio?20.07Strong
Cash Ratio?3.68Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 0 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
S&P
45
3.96FAIR▾
P/S?
S&P
3
77.51HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.9CHEAP▾
EV/Sales?
S&P
3
73.77HIGH▾
Returns & Efficiency
ROE?
S&P
3
-38.5%WEAK▾
ROA?
S&P
3
-35.9%WEAK▾
Cash Flow & Enterprise
FCF?$-121183000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day